Aurinia Pharmaceuticals Showcases LUPKYNIS’s Impact at ASN 2024
Company Announcements

Aurinia Pharmaceuticals Showcases LUPKYNIS’s Impact at ASN 2024

Story Highlights

Aurinia Pharmaceuticals (AUPH) has released an update.

Aurinia Pharmaceuticals Inc. presented new data at ASN Kidney Week 2024, highlighting the effectiveness of LUPKYNIS in treating lupus nephritis, particularly in diverse populations most affected by the disease. Real-world data showcased LUPKYNIS’s positive impact on kidney health compared to older therapies, with studies indicating improved outcomes and stronger podocyte stability at lower doses.

For further insights into AUPH stock, check out TipRanks’ Stock Analysis page.

Related Articles
Radhika Saraogi3 Best Stocks to Buy Now, 11/11/2024, According to Top Analysts 
TipRanks Auto-Generated NewsdeskAurinia Pharmaceuticals Reports Strong Growth and Strategic Restructuring
TheFlyUnusually active option classes on open November 7th
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App